A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

October 23, 2018

Study Completion Date

November 20, 2018

Conditions
AnemiaRenal Insufficiency, Chronic
Interventions
DRUG

Molidustat (BAY85-3934)

Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response

Trial Locations (20)

811-0120

Houshikai Kano hospital, Kasuya-gun

501-6062

Matsunami General Hospital, Hashima-gun

078-8211

Asahikawa-Kosei General Hospital, Asahikawa

061-3213

Ishikari Hospital, Ishikari

059-0026

Itami Kidney Clinic, Noboribetsu

060-0008

Souen Central Hospital, Sapporo

676-0812

Takasago Seibu Hospital, Takasago

306-0014

Japanese Red Cross Koga Hospital, Koga

310-0015

Mito Kyodo General Hospital, Mito

302-0011

Tokiwa Clinic, Totte

300-0062

Tsuchiura Beryl Clinic, Tsuchiura

305-0861

Kikuchi Medical Clinic, Tsukuba

986-8522

Japanese Red Cross Ishinomaki Hospital, Ishinomaki

395-8505

Iida Hospital, Iida

560-0004

Toyonaka Keijinkai Clinic, Toyonaka

187-0001

Kodaira Kitaguchi Clinic, Kodaira

263-0043

Medical corporation association Shunshin-kai Inage hospital, Chiba

810-0004

Fukuoka Renal Clinic, Fukuoka

331-8711

Ohmiya Chuo General Hospital, Saitama

990-0834

Yamagata Tokushukai Hospital, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY